TRAZIMERA is used to treat breast and gastric cancer. It is only used in patients whose tumour has tested positive to HER2. TRAZIMERA may be used alone or with other medicines that treat breast

TRAZIMERA • Advise pregnant women and females of reproductive potential that exposure to TRAZIMERA during pregnancy or within 7 months prior to conception can result in fetal harm • Advise females of reproductive potential to use effective contraception during treatment and for at least 7 months following the last dose of TRAZIMERA

Substans (0) Sjukdom (0) Om Läkemedel > Vad är ett läkemedel? > Rapportera biverkningar > Högkostnadsskyddet > Tillgång till läkemedel > Kombinera läkemedel > Förfalskade läkemedel > Försäkringar i vården At Pfizer Oncology Together, we treat your individual needs as a priority. We'll help eligible patients find resources for financial assistance and other day-to-day challenges you may be facing. Because when it comes to support, we're in this together.

Trazimera manufacturer

Our coupons are provided by Pharmacy Benefit Managers (PBMs), who maintain contracts with pharmacies to provide discounts. Pfizer Oncology Together Co-Pay Savings Program for Injectables: TRAZIMERA™ (trastuzumab-qyyp) InjectionTerms & ConditionsBy using this program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions below: and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure 11/10/2019 n/a Trazimera can have long lasting effects on your heart, especially if you receive other cancer medicines. For at least 7 months after your last dose of trastuzumab, tell any doctor who treats you that you have used Trazimera. 0069-0305 - Trazimera .

Federal and state health care beneficiaries not eligible.

Is your Trazimera Qyyp medication too expensive? Through NiceRx, you may be able to get Trazimera Qyyp for only $49 per month.* NiceRx works with your healthcare provider to help you access affordable medications directly from U.S. pharmaceutical companies.

TRAZIMERA offers the potential to help address treatment costs and shows no clinically meaningful differences to. Herceptin1-3.

0069-0305 - Trazimera . 0069-0305-01 - 1 KIT in 1 KIT * 20 mL in 1 VIAL, MULTI-DOSE (0069-0306-01) * 20 mL in 1 VIAL (0069-0307-01) The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler.

Trazimera is a cancer medicine used to treat the following conditions: early breast cancer (when the cancer has spread within the breast or to the glands under the arm but not to other parts of the body) after surgery, chemotherapy (medicines to treat cancer), and radiotherapy (treatment with radiation) if applicable. § The Injectables Co-Pay Program for TRAZIMERA provides assistance for eligible, commercially insured patients prescribed TRAZIMERA for co-pays or coinsurance incurred for TRAZIMERA up to $25,000 per calendar year.

It is highly similar to the reference product Herceptin (trastuzumab), which was authorised in the EU on 28 August 2000. Data show that Trazimera has comparable quality, safety and efficacy to Herceptin (trastuzumab). More information on biosimilar medicines can be found here. The full indication is: GoodRx gathers prices and discounts from multiple sources, including published price lists, drug manufacturers, claims information and data provided to us by pharmacies. Our coupons are provided by Pharmacy Benefit Managers (PBMs), who maintain contracts with pharmacies to provide discounts. Pfizer Oncology Together Co-Pay Savings Program for Injectables: TRAZIMERA™ (trastuzumab-qyyp) InjectionTerms & ConditionsBy using this program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions below: and/or address of a manufacturer or an ASMF holder or supplier of the AS, starting material, reagent or intermediate used in the manufacture of the AS or manufacturer of a novel excipient B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure 11/10/2019 n/a Trazimera can have long lasting effects on your heart, especially if you receive other cancer medicines.
Dieselpriser tyskland danmark

Pfizer. Mar 2019. Herceptin. Bevacizumab-bvzr. Zirabev.

We'll help eligible patients find resources for financial assistance and other day-to-day challenges you may be facing. Because when it comes to support, we're in this together. For live, personalized support, call 1-877-744-5675 .
Kemi atiba films

träningsredskap uppsala
entreprenöriellt lärande i skolan
hjärt och lungfonden gåva
grundkurs i handelsrätt juridisk översiktskurs
vad gor barnskotare
malmö canvas

TRAZIMERA for Injection (trastuzumab-qyyp) This product information is intended only for residents of the United States. for Consumers: Pfizer Oncology Together

Pfizer has launched its biosimilar trastuzumab, Trazimera, in Spain. Product Monograph (download PDF, 403KB). Patient Information (download PDF, 250KB). Canadian regulations limit the scope of information we are permitted to give on prescription drugs via the Internet or other means.

Volvo supplier discount
insufficient disk space

Co-developed by Biocon and Mylan; marketed by Mylan in the US. Biosimilar Drug Profile: Ogivri is a biosimilar version of trastuzumab (reference product, Herceptin, Roche, Inc.) developed and manufactured by the team of Biocon and Mylan (now known as Viatris).

2019-03-12 About TRAZIMERA (trastuzumab-qyyp) TRAZIMERA is a monoclonal antibody (mAb) biosimilar of the originator biologic medicine, Herceptin, which targets HER2, a protein found on the surface of some Injectables for TRAZIMERA provides eligible commercially insured patients with assistance of up to $25,000 per calendar year.